BR112017026159A2 - inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer - Google Patents

inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer

Info

Publication number
BR112017026159A2
BR112017026159A2 BR112017026159-6A BR112017026159A BR112017026159A2 BR 112017026159 A2 BR112017026159 A2 BR 112017026159A2 BR 112017026159 A BR112017026159 A BR 112017026159A BR 112017026159 A2 BR112017026159 A2 BR 112017026159A2
Authority
BR
Brazil
Prior art keywords
compounds
erk1
heterocyclic
cancer treatment
erk2 inhibitors
Prior art date
Application number
BR112017026159-6A
Other languages
English (en)
Inventor
M. Venkatesan Aranapakam
K. Thompson Scott
A. Smith Roger
P. REDDY Sanjeeva
M. DEWANG Purushottam
Hallur Gurulingappa
Mulakala Chandrika
Reddy Kethiri Raghava
Mullangi Ramesh
Zainuddin Mohd
Original Assignee
Asana Biosciences, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asana Biosciences, Llc filed Critical Asana Biosciences, Llc
Publication of BR112017026159A2 publication Critical patent/BR112017026159A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a presente invenção refere-se a novos compostos heterocíclicos e sais farmaceuticamente aceitáveis dos mesmos. também são providos métodos para preparar esses compostos. esses compostos são úteis para inibir erk1/2. com a administração a um paciente que necessita de uma quantidade terapeuticamente eficaz de um ou mais dos compostos de fórmula (i), em que x, y, z, j, m e r1 a r8 são definidos no presente documento, esses compostos são eficazes no tratamento de condições associadas com a desregulação da via ras/raf/mek/erk. uma variedade de condições pode ser tratada usando esses compostos e inclui doenças que são caracterizadas por proliferação celular anormal. em uma modalidade, a doença é câncer.
BR112017026159-6A 2015-06-15 2016-06-15 inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer BR112017026159A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562175756P 2015-06-15 2015-06-15
US62/175,756 2015-06-15
PCT/US2016/037697 WO2016205418A1 (en) 2015-06-15 2016-06-15 Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112017026159A2 true BR112017026159A2 (pt) 2018-08-14

Family

ID=56497830

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017026159-6A BR112017026159A2 (pt) 2015-06-15 2016-06-15 inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer

Country Status (18)

Country Link
US (5) US9896445B2 (pt)
EP (2) EP3842429B1 (pt)
JP (2) JP6909729B2 (pt)
KR (2) KR102644798B1 (pt)
CN (2) CN107922387A (pt)
AU (2) AU2016280717C1 (pt)
BR (1) BR112017026159A2 (pt)
CA (1) CA2986587C (pt)
DK (2) DK3307727T3 (pt)
ES (2) ES2930050T3 (pt)
FI (1) FI3307727T3 (pt)
IL (1) IL255613B (pt)
MX (2) MX2017014584A (pt)
PL (2) PL3307727T3 (pt)
PT (2) PT3307727T (pt)
RU (1) RU2017139727A (pt)
WO (1) WO2016205418A1 (pt)
ZA (1) ZA201707526B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3842429B1 (en) * 2015-06-15 2022-09-07 Asana BioSciences, LLC Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer
EP3365334B1 (en) 2015-10-21 2024-07-17 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
CN110799245B (zh) * 2017-05-16 2022-08-09 生物医学谷探索股份有限公司 用于治疗具有非典型braf突变的癌症的组合物和方法
SG11202012241RA (en) 2018-06-08 2021-01-28 Betta Pharmaceuticals Co Ltd Erk inhibitor and use thereof
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
BR112021017957A2 (pt) 2019-03-28 2021-11-23 Jiangsu Hengrui Medicine Co Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo
CA3135070A1 (en) * 2019-03-29 2020-10-08 Jiangsu Hengrui Medicine Co., Ltd. Pyrroloheterocyclic derivative, preparation method therefor, and application thereof in medicine
US20230027072A1 (en) * 2019-10-28 2023-01-26 Asana Biosciences, Llc Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2
CN111620860B (zh) * 2020-06-23 2023-02-03 济南健丰化工有限公司 一种福瑞塞替的制备方法
WO2022068860A1 (zh) * 2020-09-29 2022-04-07 江苏恒瑞医药股份有限公司 一种吡咯并杂环类衍生物的晶型及其制备方法
CN114315837B (zh) * 2020-09-29 2023-06-16 江苏恒瑞医药股份有限公司 一种erk抑制剂的结晶形式及其制备方法
TW202308633A (zh) * 2021-04-16 2023-03-01 美商艾瑞斯卡公司 Erk1/2之雜環抑制劑的用途
US20240285624A1 (en) * 2021-06-24 2024-08-29 Erasca, Inc. Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy
CA3222772A1 (en) * 2021-06-24 2022-12-29 Erasca, Inc. Erk1/2 and shp2 inhibitors combination therapy
WO2022271939A1 (en) * 2021-06-24 2022-12-29 Erasca, Inc. Erk1/2 and cdk4/6 inhibitors combination therapy
JP2024526135A (ja) * 2021-06-24 2024-07-17 エラスカ，インク． Ｅｒｋ１／２阻害剤とｋｒａｓ ｇ１２ｃ阻害剤の併用療法
TW202341999A (zh) * 2022-03-28 2023-11-01 大陸商江蘇恒瑞醫藥股份有限公司 吡咯并雜環類衍生物的富馬酸鹽的晶型及其製備方法
WO2024064690A1 (en) * 2022-09-20 2024-03-28 Erasca, Inc. Erk1/2 inhibitor polymorph forms
WO2024148307A1 (en) * 2023-01-06 2024-07-11 Erasca, Inc. Raf inhibitor and erk1/2 and/or shp2 inhibitor combination therapy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1319849B1 (it) 2000-02-18 2003-11-03 Angelo Dotta Cerotto in confezione ad apertura rapida e mezzi per la realizzazionedella stessa.
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
US6743941B2 (en) 2001-06-15 2004-06-01 Aventis Pharma Deutschland Gmbh Process for the production of piperidine derivatives
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7244735B2 (en) 2003-12-02 2007-07-17 Vertex Pharmaceuticals Inc. Heterocyclic protein kinase inhibitors and uses thereof
US20070191336A1 (en) 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
BRPI0511124A (pt) * 2004-05-14 2007-11-27 Vertex Pharma pró-drogas de inibidores de erk proteìna cinase de pirrolilpirimidina
JP2008525461A (ja) * 2004-12-23 2008-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ｅｒｋプロテインキナーゼの選択的阻害剤およびその使用
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
KR101663637B1 (ko) * 2009-11-13 2016-10-07 제노스코 키나아제 억제제
EP2697196A1 (en) 2011-04-13 2014-02-19 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
US9227969B2 (en) * 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
EP3842429B1 (en) 2015-06-15 2022-09-07 Asana BioSciences, LLC Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer
WO2017222958A1 (en) 2016-06-20 2017-12-28 Kura Oncology, Inc. Treatment of squamous cell carcinomas with inhibitors of erk
TW202023556A (zh) 2018-08-27 2020-07-01 美商庫拉腫瘤技術股份有限公司 以mapk路徑抑制劑治療腺癌
US20230027072A1 (en) 2019-10-28 2023-01-26 Asana Biosciences, Llc Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2
TW202308633A (zh) 2021-04-16 2023-03-01 美商艾瑞斯卡公司 Erk1/2之雜環抑制劑的用途

Also Published As

Publication number Publication date
US10751332B2 (en) 2020-08-25
MX2017014584A (es) 2018-02-26
AU2016280717A1 (en) 2017-12-21
CA2986587A1 (en) 2016-12-22
ES2930050T3 (es) 2022-12-05
US20160362407A1 (en) 2016-12-15
ZA201707526B (en) 2018-11-28
US11103491B2 (en) 2021-08-31
EP3307727B1 (en) 2023-10-04
EP3307727A1 (en) 2018-04-18
JP6909729B2 (ja) 2021-07-28
EP3842429B1 (en) 2022-09-07
PT3307727T (pt) 2024-01-12
JP2021105004A (ja) 2021-07-26
JP2018517685A (ja) 2018-07-05
CA2986587C (en) 2024-03-12
KR102644798B1 (ko) 2024-03-08
AU2020273302B2 (en) 2022-08-11
WO2016205418A1 (en) 2016-12-22
ES2968007T3 (es) 2024-05-06
US20170362216A1 (en) 2017-12-21
US9896445B2 (en) 2018-02-20
EP3842429A1 (en) 2021-06-30
US20230051842A1 (en) 2023-02-16
PT3842429T (pt) 2022-11-21
AU2016280717B2 (en) 2020-12-03
CN107922387A (zh) 2018-04-17
US20200179356A1 (en) 2020-06-11
DK3842429T3 (da) 2022-11-07
AU2016280717C1 (en) 2021-05-13
KR102644788B1 (ko) 2024-03-08
PL3842429T3 (pl) 2023-02-20
IL255613A (en) 2018-01-31
DK3307727T3 (da) 2024-01-08
MX2021000148A (es) 2021-03-25
US11925629B2 (en) 2024-03-12
CN113200961A (zh) 2021-08-03
JP7093438B2 (ja) 2022-06-29
FI3307727T3 (fi) 2024-01-08
RU2017139727A (ru) 2019-07-16
KR20210022160A (ko) 2021-03-02
PL3307727T3 (pl) 2024-07-08
CN113200961B (zh) 2023-12-22
IL255613B (en) 2021-03-25
US10471051B2 (en) 2019-11-12
KR20180014706A (ko) 2018-02-09
AU2020273302A1 (en) 2020-12-17
US20160362406A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
BR112017026159A2 (pt) inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
BR112019007144A2 (pt) compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
BR112019007143A2 (pt) compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
BR112018000808A2 (pt) compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
BR112014028954A2 (pt) amidas de n-piridinila substituídas no anel como inibidores da quinase
BR112019006047A2 (pt) compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
EA201792116A1 (ru) Ингибитор янус-киназы
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
BR112015021549A2 (pt) inibidores de piridina cinase cdk9
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112015003729A2 (pt) composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
BR112015023356A2 (pt) inibidores de quinase pirrol[2,3-b]piridina cdk9

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]